Condition/Procedure Measure Compliance Criteria Reference Attribution Method
|
|
- Noah Owens
- 5 years ago
- Views:
Transcription
1 Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is designed to be used in conjunction with the UnitedHealth Premium Program Methodology document. To understand the methodology used for the Premium program, it is important to review the entire methodology. Quality is the primary program measurement, evaluated using national standardized measures. Listed below by condition/procedure are the measures used to evaluate physicians in the Cardiology Premium specialty. Measures are applied to the commercial, Medicare and Medicaid patient populations, unless otherwise noted. For information regarding measure attribution, please refer to the Attribution Methods document in the Methodology Documents section on the Premium Methodology page. Condition/Procedure Measure Compliance Criteria Reference Attribution Method Annual Monitoring for s on Persistent Medications Atrial Fibrillation Adult patient(s) persistently taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) who received a serum potassium AND serum creatinine within the last 12 reported months Adult patient(s) persistently taking digoxin who received a serum potassium, serum creatinine, AND digoxin level test within the last 12 reported months Adult patient(s) persistently taking diuretics who received a serum potassium AND serum creatinine within the last 12 reported months (s) at high risk for thromboembolism who are currently taking warfarin, or an oral thrombin inhibitor, or an oral factor Xa inhibitor (s) compliant with prescribed oral factor Xa inhibitor (minimum compliance 80%) persistently taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) had a serum potassium AND serum creatinine test persistently taking digoxin had a serum potassium, serum creatinine, AND digoxin level test persistently taking diuretics had a serum potassium AND serum creatinine at high risk for thromboembolism had warfarin, or an oral thrombin inhibitor, or an oral factor Xa inhibitor medication dispensed was 80% or more compliant with prescribed oral factor Xa inhibitor medication Cerebral Vascular Accident & Transient Cerebral Ischemia (Stroke) (s) compliant with prescribed clopidogrel (minimum compliance 80%) (s) with a low-density lipoprotein (LDL cholesterol) test in last 24 reported months was 80% or more compliant with prescribed clopidogrel medication had an LDL cholesterol test
2 Cerebral Vascular Accident (s) with a recent acute cerebral ischemic event that & Transient Cerebral with an acute cerebral ischemic event had a had a carotid Doppler or head/neck angiography test in last Ischemia (Stroke) carotid Doppler or head/neck angiography test 12 reported months (continued) (s) currently taking a beta-blocker specifically recommended for congestive heart failure management had a beta-blocker medication dispensed for CHF (s) currently taking an ACE inhibitor or acceptable alternative had an ACE inhibitor or acceptable alternative medication dispensed Congestive Heart Failure (s) not taking contraindicated Class I antiarrhythmic medication (excludes patients with diastolic heart failure) did not have a contraindicated Class I antiarrhythmic medication dispensed (s) that did not have a congestive heart failure related emergency department encounter in last 12 reported months did not have a CHF-related emergency department encounter Congestive Heart Failure: Hospitalization (s) that did not have a congestive heart failure related hospitalization in last 12 reported months (s) with a recent hospitalization for congestive heart failure that had any provider visit within 7 days of hospital discharge 180 Day Redo: Measures whether patients did not have a redo procedure within 180 days after did not have a CHF-related hospitalization with a recent hospitalization for congestive heart failure had a visit with any provider did not have a redo procedure within 180 days after the assessed procedure Coronary Artery Catheterization - Diagnostic Major Restudy: Measures whether the patients did not have a major restudy did not have a hemorrhage, pneumonia, did not have advanced imaging (e.g., CT) within 365 days after the assessed procedure 31 to 365 Day Redo: Measures whether patients did not have a redo procedure within 31 and 365 days after a primary interventional cardiology procedure did not have a redo procedure within 31 and 365 days after the assessed procedure
3 did not have a hemorrhage, pneumonia, Major Restudy: Measures whether the patients did not have a major restudy did not have advanced imaging (e.g., CT) within 365 days after the assessed procedure Coronary Artery Catheterization with Drug Stent (continued) 31 to 365 Day Redo: Measures whether patients did not have a redo procedure within 31 and 365 days after a primary interventional cardiology procedure did not have a redo procedure within 31 and 365 days after the assessed procedure did not have a hemorrhage, pneumonia, Major Restudy: Measures whether the patients did not have a major restudy did not have advanced imaging (e.g., CT) within 365 days after the assessed procedure (s) compliant with prescribed beta-blocker-containing medication (minimum compliance 80%) was 80% or more compliant with prescribed beta-blocker-containing medication Coronary Artery Disease (s) currently taking an ace-inhibitor or angiotensin II receptor antagonist had an ACE-inhibitor or angiotensin receptor antagonist medication dispensed (s) that did not have a coronary artery disease related emergency department encounter in last 12 reported months did not have a coronary artery diseaserelated emergency department encounter (s) years of age that had a HbA1c test in last 12 reported months had a HbA1c test Diabetes (s) years of age that had annual screening for nephropathy or evidence of nephropathy (s) compliant with prescribed ACE-inhibitor-containing medication (minimum compliance 80%) (s) taking insulin with evidence of self-monitoring blood glucose testing had annual screening for nephropathy or evidence of nephropathy was 80% or more compliant with prescribed ACE-inhibitor-containing medication taking insulin had self-monitoring blood glucose testing
4 Diabetes (continued) Diabetes (Biguanide- (s) that did not have a diabetes related emergency department encounter in last 12 reported months (s) with a diagnosis of diabetic nephropathy, proteinuria, or chronic renal failure currently taking an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor antagonist (s) compliant with prescribed biguanide-containing medication (minimum compliance 80% or higher) (Medicare only) did not have a diabetes-related emergency department encounter with diabetic nephropathy, proteinuria, or chronic renal failure had an ACE inhibitor or angiotensin receptor antagonist medication dispensed was 80% or more compliant with prescribed biguanide-containing medication Diabetes (Dipeptidylpeptidase (DPP)-4- (NS) (s) compliant with prescribed dipeptidyl peptidase (DPP)-4 inhibitor-containing medication (minimum compliance 80% or higher) (Medicare only) was 80% or more compliant with prescribed dipeptidyl peptidase (DPP)-4 inhibitor-containing medication Diabetes (Sulfonylurea- (s) compliant with prescribed sulfonylurea-containing medication (minimum compliance 80% or higher) (Medicare only) was 80% or more compliant with prescribed sulfonylurea-containing medication Diabetes (Thiazolidinedione- (s) compliant with prescribed thiazolidinedionecontaining medication (minimum compliance 80% or higher) (Medicare only) was 80% or more compliant with prescribed thiazolidinedione-containing medication Diabetes Medications-Part D Medication (s) compliant with all prescribed diabetes medications (minimum compliance 80% or higher) (Medicare only) was 80% or more compliant with all prescribed diabetes medications Hypertension (s) that had a serum creatinine in last 12 reported months had a serum creatinine test Invasive Therapeutic Electrophysiology (Ablation) Ablation Redo: Measures whether patients did not have a redo ablation within 180 days after original ablation did not have a redo ablation within 180 days after the assessed ablation
5 Invasive Therapeutic Electrophysiology (Ablation) (continued) did not have a hemorrhage, pneumonia, Elderly patients who had an accidental fall or hip fracture who did not take an anticonvulsant; nonbenzodiazepine hypnotic; SSRI; antiemetic; antipsychotic; benzodiazepine; or tricyclic antidepressant after the incident with an accidental fall or hip fracture did not have an anticonvulsant, nonbenzodiazepine hypnotic, SSRI, antipsychotic, benzodiazepine, or tricyclic antidepressant medication dispensed after the incident Medication Safety Monitoring Elderly patients with chronic kidney disease who did not take a Cox-2 selective or nonaspirin nonsteroidal antiinflammatory drug (NSAID) after the earliest record of chronic kidney disease with chronic kidney disease did not have a Cox-2 selective or nonaspirin nonsteroidal antiinflammatory drug (NSAID) dispensed after the earliest record of chronic kidney disease Elderly patients with dementia who did not take an antiemetic; antipsychotic; benzodiazepine; tricyclic antidepressant; H2 receptor antagonist; nonbenzodiazepine hypnotic or anticholinergic agent after the earliest record of dementia with dementia did not have an antipsychotic, benzodiazepine, tricyclic antidepressant, H2 receptor antagonist, nonbenzodiazepine hypnotic or anticholinergic agent dispensed after the earliest record of dementia Persistence of Beta-Blocker (s) hospitalized with an acute myocardial infarction (AMI) persistently taking a beta-blocker for six months after discharge hospitalized with acute myocardial infarction (AMI) had persistent beta-blocker medication therapy for six months after discharge Renin Angiotensin System (RAS) Antagonists-Part D Medication (s) compliant with prescribed renin-angiotensin system antagonist medication (minimum compliance 80% or higher) (Medicare only) was 80% or more compliant with prescribed RAS antagonist medication Statin Therapy for s with Cardiovascular Disease Men years of age with cardiovascular disease that received a high or moderate-intensity with cardiovascular disease had a high or moderate-intensity dispensed
6 Men years of age with statin adherence (proportion of was 80% or more compliant with prescribed days covered) at least 80% during the treatment period Statin Therapy for s with Cardiovascular Disease (continued) Statin Therapy for s with Diabetes Statins- Use of High-Risk Medications in the Elderly Women years of age with cardiovascular disease that received a high or moderate-intensity Women years of age with statin adherence (proportion of days covered) at least 80% during the treatment period (s) years of age with diabetes that received a (s) with statin adherence (proportion of days covered) at least 80% during the treatment period (s) compliant with prescribed (minimum compliance 80% or higher) (Medicare only) s 66 years of age and older who did not receive one or more high-risk medications in the elderly in the last 12 reported months (HEDIS criteria) with cardiovascular disease had a high or moderate-intensity dispensed was 80% or more compliant with prescribed with diabetes had a dispensed was 80% or more compliant with prescribed was 80% or more compliant with prescribed did not have a high-risk medication dispensed Recognition Programs The Premium program also counts National (NCQA) and Bridges to Excellence (BTE) recognition programs towards quality assessment. The Premium program adds the greater of 25 measures or 10 percent of the physician s total measures (whichever is larger) as compliant to the quality assessment for physicians who have achieved recognition in one or more of these programs applicable to their Premium specialty. National Diabetes Heart/Stroke Bridges to Excellence Program Cardiac Care Congestive Heart Failure Care Coronary Artery Disease Care Diabetes Care Hypertension Care UnitedHealth Premium Program
MEASURING CARE QUALITY
MEASURING CARE QUALITY Region November 2016 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
More informationMEASURING CARE QUALITY
MEASURING CARE QUALITY Region December 2013 For Clinical Effectiveness of Care Measures of Performance From: Healthcare Effectiveness Data and Information Set (HEDIS ) HEDIS is a set of standardized performance
More informationQUALITY IMPROVEMENT Section 9
Quality Improvement Program The Plan s Quality Improvement Program serves to improve the health of its members through emphasis on health maintenance, education, diagnostic testing and treatment. The Quality
More informationSupplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationNote: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.
COMMUNITY PHARMACY V1.1 MANDATORY S Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. # NAME DESCRIPTION NUMERATOR DENOMINATOR
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationNote: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis.
Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. DESCRIPTION NUMERATOR DENOMINATOR DM2012-12 Portion of Days Covered
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationPharmacy Benefit Management
Benefit Management Measures At A Glance Updated: 10/8/2015 Page 1 of 7 Benefit Management Mandatory Measures (6) Note: Mandatory measures are those measures that are a requirement of accreditation and
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More information2016 Internal Medicine Preferred Specialty Measure Set
1 0059 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period 5 0081 Registry, EHR, 9 0105
More informationMEASURE STEWARD Pharmacy Quality Alliance (PQA) D ATA SOURCE Enrollment; U R A C DOMAIN Engagement & Experience of Care
MANDATORY S Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual basis. DM2012-12 DTM2015-01 Portion of Days Covered (PDC) Adherence
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
More information2016 General Practice/Family Practice Preferred Specialty Measure Set
1 0059 5 0081 41 N/A 50 N/A 65 0069, EHR 66 0002, EHR Effective Clinical Care Effective Clinical Care Effective Clinical Care Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients
More informationPatient-Centered Primary Care Scorecard Measures
Patient-Centered Primary Care Scorecard Measures Acute and Chronic Care Management Measures Medication Adherence Proportion of Days Covered (PDC): Oral Diabetes Identifies patients with at least two prescriptions
More informationCLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016
CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016 WHAT IS AN EPISODE OF CARE? An episode of care is a grouping of a patient s health care claims for a unique
More informationSTARS SYSTEM 5 CATEGORIES
TMG STARS 2018 1 2 STARS Program Implemented in 2008 by CMS. Tool to inform beneficiaries of quality of various health plans 5-star rating system Used to adjust payments to health plans (bonus to plans
More informationSupplementary Online Content
Supplementary Online Content Choudhry NK, Krumme AA, Ercole PM, et al. Effect of reminder devices on medication adherence: the REMIND randomized clinical trial. JAMA Int Med. Published online February
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More information2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT
2017 URAC PHARMACY BENEFIT MANAGEMENT PERFORMANCE MEASUREMENT: AGGREGATE SUMMARY PERFORMANCE REPORT December 2017 Table of Contents Executive Summary... 1 Pharmacy Benefit Management Organization Characteristics...
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationConsensus Core Set: Cardiovascular Measures Version 1.0
Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized
More informationTable 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings
CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience
More informationSupplementary Online Content
Supplementary Online Content Lee C-C, Lee M-tG, Chen Y-S. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Internal Medicine. Published online October 5, 2015.
More informationproposed set to a required subset of 3 to 5 measures based on the availability of electronic
CMS-0033-P 143 proposed set to a required subset of 3 to 5 measures based on the availability of electronic measure specifications and comments received. We propose to require for 2011 and 2012 that EP's
More information2017 HEDIS Measures. PREVENTIVE SCREENING 2017 Measure Quality Indicator
PREVENTIVE SCREENING Childhood Immunization Children who turn 2 during the Adolescent Immunization Adolescents who turn 13 during the Lead Screening Children who turn 2 during the Breast Cancer Screening
More informationSTOPP and START criteria October 2011
# START and STOPP are newer criteria to identify potentially inappropriate medications in elderly, including drug drug and drug disease interactions, drugs which increase risk of falls and drugs which
More information2012 Core Measures. Acute Myocardial Infarction (AMI)
2012 Core Measures Acute Myocardial Infarction (AMI) Aspirin at Arrival Aspirin Prescribed at Discharge Angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for left ventricular
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationAnthem Blue Precision Quality Designation Methodology Summary 2017
This document outlines Anthem s Blue Precision methodology for measuring Physician Quality. Anthem has physician quality transparency programs for physicians practicing in the following specialties: Allergy/Immunology,
More informationCommercial HMO/POS Effectiveness of Care Measure
Commercial HMO/POS Effectiveness of Care Measure HEDIS 2017 NCQA Quality Compass National Average Adult BMI Assessment 91.85% 76.17% Weight Assessment and Counseling for Nutrition and Physical Activity
More informationDisease Management. Measures At A Glance
s At A Glance Updated: 11/2/2017 Page 1 of 7 Cross Cutting Mandatory s (4) Note: Mandatory measures are those measures that are a requirement of accreditation and must be reported to URAC on an annual
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationSupplementary Online Content
Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationCOMMUNITY HEALTH GROUP HEDIS MEASURES (CY 2012) MEDICARE QUICK REFERENCE GUIDE FOR BILLING DEPARTMENT
HEDIS MEASURES (CY ) MEDICARE QUICK REFERENCE GUIDE FOR BILLING DEPARTMENT Care for Older Adults Colorectal Cancer Screening Annual Monitoring for Patients on Persistent Medications COA COL MPM Age Description
More informationProvider Toolkit. Y0067_PR_Tlkt_0316 IA 03/09/2016
Provider Toolkit 2016 2017 Y0067_PR_Tlkt_0316 IA 03/09/2016 PFFS/PPO/TOHMO TABLE OF CONTENTS Sample Letter from Physician to Patient...4 HEDIS Quick Reference Guide...5 Fax Cover Sheet...10 Preventive
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationMeasure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner
2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationGuidelines for Management of Chronic Conditions
Guidelines for Management of Chronic Conditions 1. DIABETES: If you have high blood sugar or Diabetes, the following are recommended: Goals to prevent progression of diabetes and reducing complications
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationOverview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists
Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Measure Name Measure Domain Measure Focus Comment/Explanation CMS Value-based Purchasing Program (CMS VBP) AMI 30-day
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationProvider STAR Ratings Quick Reference Guide 2016 Dates of Service. Updated January 20, 2016
Provider STAR Ratings Quick Reference Guide 2016 Dates of Service Updated January 20, 2016 Adult BMI (Body Mass Index) Assessment (ABA) EXCLUSIONS: Members who have a diagnosis of pregnancy during the
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationCVD Outcomes Aggregate Report Report Period: 05/01/ /30/2004
Changes in JNC VII Blood Pressure Categories Blood Pressure Category Initial Value ¹ Latest Value ¹ Improvement ² (Based on JNC VII Guidelines) values (days) (N=271) (N = 209) Normal (SBP < 120 and DBP
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationCardiovascular Disorders. Heart Disorders. Diagnostic Tests for CV Function. Bio 375. Pathophysiology
Cardiovascular Disorders Bio 375 Pathophysiology Heart Disorders Heart disease is ranked as a major cause of death in the U.S. Common heart diseases include: Congenital heart defects Hypertensive heart
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationPharmacy Technician Course
Pharmacy Technician Course VERSION HISTORY SECTION 1: History and Scope of the Pharmacy Technician Scope of the Pharmacy Technician Section 1 Quiz Check Your Knowledge Section 1 Quiz Answers SECTION 2:
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationMultidisciplinary Geriatric Trauma Care Guideline
Multidisciplinary Geriatric Trauma Care Background Traumatic injury in the geriatric population is increasing in prevalence and is associated with higher mortality and complication rates comparted to younger
More informationDefinitions of chronic conditions used to define the number of serious comorbidities in the study.
Supplementary Table 1 Definitions of chronic conditions used to define the number of serious comorbidities in the study. Comorbidity ICD-9 Code Description CAD/MI 410.x Acute myocardial infarction 411.x
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationImproving Quality of Care for Medicare Patients: Accountable Care Organizations
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE
More informationPrescribe appropriate immunizations for. Prescribe childhood immunization as per. Prescribe influenza vaccinations in high-risk
Supplemental Digital Appendix 1 46 Health Care Problems and the Corresponding 59 Practice Indicators Expected of All Physicians Entering or in Practice Infectious and parasitic diseases Avoidable complications/death
More informationHEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications
HEDIS Quick Reference Guide Updated to reflect NCQA HEDIS 2016 Technical Specifications Fidelis SecureCare strives to provide quality healthcare to our membership as measured through HEDIS quality metrics.
More informationMeasure Owner Designation. AMA-PCPI/NCQA (contract) is the measure owner. AMA-PCPI is the measure owner. AMA-PCPI/ASCO/NCCN is the measure owner
2012 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationThe Future of Cardiac Care: Managing Our Patients Together
The Future of Cardiac Care: Managing Our Patients Together Charles R. Caldwell, MD, FACC Disclosures: iheartdoc,inc. Telemedicine 1 MACRA Medicare Access and CHIP Reauthorization Act of 2015 Repealed the
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationPatient enrolment details CKDOD registry
Patient enrolment details CKDOD registry Personal Information Date of enrolment D D Date of birth D D Gender Descent Height cm m History of smoking Y N U Date of first diagnosis of CKD D D Primary Cause
More informationOBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP
OBSERVATIONAL Patient-centered observational analytics: New directions toward studying the effects of medical products Patrick Ryan on behalf of OMOP Research Team May 22, 2012 Observational Medical Outcomes
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationFor Electronic Measure Specification Information go to:
Diabetes Recognition NQF 0421 PQRI 128 Title: Adult Weight Screening and Follow-Up Description: Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the
More information2018 MIPS Reporting Family Medicine
2018 MIPS Reporting Family Medicine Quality Reporting Requirements: Report on 6 quality measures or a specialty measure set Include at least ONE outcome or high-priority measure Report on patients of All-Payers
More informationMeasurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #44 (NQF 0236): Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR
More informationGeri-PARDY! (2015 Beers Criteria) Pharmacology Edition
Geri-PARDY! Pharmacology Edition (2015 Beers Criteria) Aurelio Muyot, MD, AGSF, FACP Assistant Professor College of Osteopathic Medicine Touro University Nevada Objectives Review the 2015 Beers Criteria
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationStar Measures At-A-Glance Guide
Star Measures At-A-Glance Guide This guide alerts you to important preventive care and services that you can provide to patients to help boost Star Ratings. ASSESSMENT AND SCREENING At WellCare, we value
More informationUTHEALTH HOUSTON CCTS BIOBANK VARIABLE LIST
Please check the requested variables:, and/or. Obtained at Initial Hospital Recruitment Demographics: Age Gender Marital Status Ethnicity Race Height (inches) Weight (pounds) Main language spoken Socioeconomic
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationSUNY Downstate Medical Center/University Hospital Oct - Dec 2013 (Q4)
Value Based Purchasing-Clinical Process of Care Measures Denom Observed VBP VBP Benchmark Standard Denom Observed VBP VBP Benchmark Standard N Percent x/n N Percent x/n SCIP-Inf-9 Urinary catheter removed
More informationGWTG Post-Discharge Follow-up Form
Bold font = Required field Patient ID: Date of Hospital Admission: / / mm / dd / yyyy Date Follow-up Completed: / / mm / dd / yyyy PATIENT LOGISTICS Method used for Patient follow-up: Chart Review Health
More information